Patient Cost Rising While Generic Prices Fall Doesn’t Add Up
WASHINGTON DC (October 23, 2019) – The Association for Accessible Medicines (AAM) today launched its seven-figure #DoesntAddUp advertising campaign to raise awareness among policymakers of the generic and biosimilar industry’s significant market access challenges and promote potential solutions to ensure patients can access their medicines.
A website, DoesntAddUp.com, is the destination for those experiencing the new ads running across cable, digital platforms and print. Visitors to the site can access a recently published series of white papers that quantify the growing barriers that keep generics and biosimilars from getting approved, launching onto the market, staying on the market and being covered for patients.
“This campaign explains why patient costs are going up when generic prices are falling, and explores ways to fix that untenable dynamic,” said Chip Davis, CEO of the Association for Accessible Medicines. “Educating policymakers is the first step toward remedying these challenges on behalf of America’s patients.”
The cable spots, which feature patients who were compensated for their participation, can be viewed here:
AAM is publishing a series of white papers this fall that are available on DoesntAddUp.com, including:
- 2019 Generic Drug and Biosimilars Access & Savings Report
- Failure to Launch Part 1: Patent Abuse Blocks Access to Biosimilars for America's Patients - $7.6 Billion in Lost Savings
- Failure to Launch Part 2: Barriers to Biosimilar Market Adoption - $2.2 Billion in Lost Savings
- Access Denied: Why New Generics Are Not Reaching America’s Seniors – Patients Could Be Saving $4 Billion Annually
- Generic substitution – coming soon
- Generic out-of-pocket costs – coming soon
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.
